Research status of hemorrhagic cystitis after hematopoietic stem cell transplantation
10.3760/cma.j.cn115356-20240318-00037
- VernacularTitle:造血干细胞移植后出血性膀胱炎的研究现状
- Author:
Changting CHEN
1
;
Zengzheng LI
;
Shuai FENG
;
Tonghua YANG
Author Information
1. 昆明理工大学医学院，昆明 650500
- Keywords:
Hematopoietic stem cell transplantation;
Hemorrhagic cystitis;
Graft vs host disease;
Drug therapy;
Viral infection
- From:
Journal of Leukemia & Lymphoma
2025;34(4):253-256
- CountryChina
- Language:Chinese
-
Abstract:
After more than 70 years of development, hematopoietic stem cell transplantation (HSCT) has become an important method to cure malignant hematological tumors in hematology department. However, postoperative hemorrhagic cystitis (HC) mainly caused by radiotherapy and chemotherapy drugs, viral infection and graft-versus-host disease (GVHD) has a high mortality rate, which is an important factor affecting the transplantation efficacy of patients. In addition to traditional treatments, some new treatment options have been discovered in recent years. At present, the main treatment options for this disease include preventive treatment, antiviral treatment, surgical treatment, traditional Chinese medicine treatment, and GVHD treatment. This article reviews the latest progress in the treatment of HC after HSCT at home and abroad in recent years, and discusses the advantages and disadvantages of different treatment methods.
